Clinical Trials Logo

Advanced Melanoma clinical trials

View clinical trials related to Advanced Melanoma.

Filter by:

NCT ID: NCT04462406 Recruiting - Advanced Melanoma Clinical Trials

Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial

Start date: February 9, 2021
Phase: Phase 2
Study type: Interventional

This phase II trial investigates how well biomarkers on PET/CT imaging drive early discontinuation of anti-PD-1 therapy in patients with stage IIIB-IV melanoma that cannot be removed by surgery (unresectable). Anti-PD-1 therapy has become a standard therapy option for patients with unresectable melanoma. This trial is being done to determine if doctors can safely shorten the use of standard of care anti-PD1 therapy for melanoma by using biomarkers seen on PET/CT imaging and tumor biopsy.

NCT ID: NCT03917069 Recruiting - Advanced Melanoma Clinical Trials

Nab-PCE vs PC for MM After Failure of Anti-PD-1

Start date: March 23, 2019
Phase: Phase 2
Study type: Interventional

This is a randomized controlled clinical trial of nab-paclitaxel + carboplatin - Endostatin for advanced melanoma after failure of PD-1 therapy. The aim was to evaluate the efficacy and safety of nab-paclitaxel+carboplatin - endostatin versus combination of paclitaxel and carboplatin in patients with advanced melanoma after failure of PD-1 therapy.

NCT ID: NCT03818893 Recruiting - Advanced Melanoma Clinical Trials

Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII

Start date: March 2019
Phase: Phase 2
Study type: Interventional

This is a multi-center, open-labeled, non-randomized, single arm investigator-initiated trial to evaluate the safety and efficacy of GEN0101 and Pembrolizmub combination in patients with advanced melanoma.

NCT ID: NCT03422445 Recruiting - Advanced Melanoma Clinical Trials

A Study of Apatinib Combined With Temozolomide in Patients Witn Advanced Melanoma

Start date: January 8, 2018
Phase: Phase 2
Study type: Interventional

30 patients with advanced melanoma will receive apatinib plus Temozolomide as maintenance therapy.

NCT ID: NCT03311308 Recruiting - Advanced Melanoma Clinical Trials

A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma

Start date: February 7, 2018
Phase: Phase 1
Study type: Interventional

The purpose of this study is to evaluate the effectiveness and safety of the combination of Pembrolizumab (KEYTRUDA®) and the investigational drug, Metformin.

NCT ID: NCT01614301 Recruiting - Advanced Melanoma Clinical Trials

Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma

Start date: May 2012
Phase: Phase 1/Phase 2
Study type: Interventional

A prospective phase I and consecutive phase II, twoarm, randomized multi-center trial of temsirolimus in combination with pioglitazone, etoricoxib and metronomic low-dose trofosfamide versus dacarbazine (DTIC) in patients with advanced melanoma Phase I: To determine the dose of temsirolimus to be used in phase II part of the study Phase II: To determine overall survival Secondary objectives - To evalulate response rate - To evaluate time to progression (TTP) - To evalulate time to partial response (time to PR or better)(TPR) - To evaluate quality of life - To evaluate tolerability and safety

NCT ID: NCT00813449 Recruiting - Advanced Melanoma Clinical Trials

Safety Study of Combined Chemotherapy and Endostar to Untreated Patients With Advanced Melanoma

melanoma
Start date: August 2008
Phase: Phase 2
Study type: Interventional

Multicenter, double-blinding, randomized controlled, phase II clinical trial on combined chemotherapy of Endostar (Recombinant Human Endostatin) for untreated patients with advanced melanoma, To compare the efficacy and safety of Endostar combined with Dacarbazine and monotherapy of Dacarbazine for advanced melanoma